On the other board, someone talked about 'averaging up'. I

New Post Public Reply Private Reply Replies (0) Message Board
joey68
On the other board, someone talked about 'averaging up'. I agree with this concept.

In an older post I talked about the benefits of averaging up. You see, the majority of people in these boards brag about averaging down.

we read things such as, "Buying on the dips!" and "Just bought a million more". We hear these things, but how often do we read about these investors making big bucks? I personally believe many online investors live the life of owning millions and million of shares yet they never make a decent profit.

Averaging up on the other hand is what makes the price increase. When we average up, we show confidence in the company; which in turn interests new investors to investigate.

Sure, averaging down is fun because we get to own millions of shares, but in the end...owning a billion shares which ultimately never become worth something are just that... worthless.


Heres the original post from March of this year:

Quote:
Short term investors place extra burdens on companies because they are skittish about volatility. Unlike short term investors who base the majority of their investment decisions on the color of a candle, long term investors help create value.

Long term investors don't only try to average down, they try to average UP; meaning, they buy shares as the price goes UP. It's called Pyramiding. Google it. Its very interesting stuff. As the price goes up, they continually buy less number of shares for a higher price.

Why do investors average up? Because it only further enhances the value of the company. Whats the point in averaging down and owning 50 million shares in one company if you only buy as the price goes down? (There's nothing wrong with owning millions of shares; the point being its important to know when to SELL).

Many investors fall for the 'its a gift' thing far too often.

On the other hand, averaging UP increases the stocks visibility to more investors.

Many investors average down with the notion that they are getting shares at 'value' prices. They say things such as:

"Just bought another 100,000 on this dip!"
or
"These are gift prices! Get them while you can!"

I respect investors decisions to think like this, but for myself, the thinking is backwards. Averaging up reassures you that you found a great stock. Averaging down can actually hurt you because when you average down, your position keeps getting bigger, and if the stock never recovers, your losses will end up being greater than if you simply kept your original position.

The downfall for many investors is not knowing when to SELL. They stay in, watch the price skyrocket, but never sell thinking it will go higher. But the price crashes and end up taking a total loss. Those 50 million 'gift' shares are now worth nothing.


Not investment advice

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 0

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Drunk Angel Celebrates First Year in Crystal Jewelry

Updated Category News Views 2

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

Continue Reading
Celebree Elevates Early Ed with New Certification Push

Updated Category News Views 0

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Continue Reading
Lida Group Expands Global Modular Construction Services

Updated Category News Views 5

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Continue Reading
Jollibee and DreamWorks Unite for Cultural Celebration

Updated Category News Views 1

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 3

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Updated Category News Views 3

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading

Top 5 Most Recently Viewed Articles

Neumora Therapeutics: Upcoming Financial Results and Insights

Updated Category News Views 123

Neumora Therapeutics to Announce Financial Results Neumora Therapeutics, Inc. (Nasdaq: NMRA), a pioneering biopharmaceutical firm, is gearing up to share its financial outcomes for the second quarter of a future year. The conference call is set for 4:30 p.m. ET on a Wednesday, and this event aims to deliver important updates regarding their business and strategic...

Continue Reading
Exciting Insights into Claudin 6 Targeted Therapy for Cancer

Updated Category News Views 165

Introduction to TORL BioTherapeutics and TORL-1-23 TORL BioTherapeutics, LLC is leading the way in developing innovative cancer treatments, particularly focusing on antibody-drug conjugates that target Claudin 6. Their flagship product, TORL-1-23, has shown significant potential in recent clinical trials specifically aimed at patients with Claudin 6 positive cancers. This...

Continue Reading
Understanding Plasma Biomarkers for Liver Health in Youth

Updated Category News Views 118

Plasma Biomarkers and Liver Health in Adolescents Recent research has unveiled an exciting advancement in pediatric medicine regarding liver health in adolescents, particularly among Latino youth facing obesity. The study, conducted by the Children's Hospital Los Angeles, led by Principal Investigator Michael Goran, PhD, has explored the potential of plasma-based...

Continue Reading
Gruma's Market Control: A Look at Price Fixing in Mexico

Updated Category News Views 119

Cofece Ruling on Gruma's Price Fixing Authority In a significant decision that has set the stage for future pricing strategies, Mexico's antitrust authority, Cofece, announced that Gruma, a prominent player in the corn flour and tortilla market, has the ability to fix prices. This conclusion was reached following a comprehensive investigation, which revealed a lack of...

Continue Reading
Coloplast A/S Unveils Strong Financial Performance for 2024/25

Updated Category News Views 190

Coloplast A/S Interim Financial Highlights for 2024/25 Coloplast A/S has recently announced its interim financial results for the period from 1 October 2024 to 30 June 2025. This report unveils the company's impressive organic growth and highlights its strategies for maintaining its market position. Remarkable Growth Figures The latest results showcase an organic growth...

Continue Reading